Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

University of Pennsylvania85 enrolled

Overview

The investigators hypothesized that: 1\) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

Conditions

Gastroesophageal Reflux Disease Diabetic Gastroparesis

Interventions

intervention letterOTHER

Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components: 1. The name and medical record # of the patients involved 2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy 3. A reminder of the adverse effect of long-term metoclopramide therapy 4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients 5. A request that the physician document the discontinuation trial in the electronic medical record

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Physicians at University of Pennsylvania Health System who ordered an active metoclopramide prescription with a questionable indication. Exclusion Criteria: * Physicians-in-training (e.g., residents, fellows) * Physicians how were investigators on this study * Physicians serving on the the University of Pennsylvania Drug Use and Effects Committee or Information Technology Oversight Board

Locations (1)

University of Pennsylvania Center for Clinical Epidemiology and Biostatistics

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Discontinuation of metoclopramide therapy

Twelve weeks after the intervention period, we searched the medical records of patients in the intervention and non-intervention groups to determine whether discontinuation of metoclopramide therapy had taken place.

Time frame: 12 weeks after intervention period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.